Husnain Ali, Aadam Abdul Aziz, Keswani Rajesh, Sinha Jasmine, Caicedo Juan Carlos, Duarte Andres, Stiff Kristine, Reiland Allison, Cacho Daniel Borja, Salem Riad, Riaz Ahsun
Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL 60611, United States.
Department of Medicine, Section of Gastroenterology and Hepatology, Northwestern Memorial Hospital, Chicago, IL 60611, United States.
Br J Radiol. 2025 Jan 1;98(1165):124-130. doi: 10.1093/bjr/tqae204.
To assess the safety and effectiveness of percutaneous endobiliary radiofrequency ablation (EB-RFA) in the management of refractory benign biliary strictures.
Percutaneous EB-RFA was performed in 15 individuals (M/F = 8/7; median age: 57 [33-84]) for benign biliary strictures resistant to traditional methods (transhepatic cholangioplasty and biliary drains). All patients underwent ≥1 unsuccessful cholangioplasty session and upsizing of their transhepatic biliary drains pre-procedure. Technical and clinical success were defined as luminal gain with enhanced flow and a lack of clinically evident recurrent stricture on follow-up after drain/stent removal, respectively.
A total of 16 EB-RFA procedures were performed. Technical success rate was 100% (16/16). Procedure-related complications occurred in 1/16 cases (drain leakage with subsequent cellulitis). Clinical success rate was 87% (13/15) with a median follow-up of 17 (2-24) months. Drain/stent was not removed in one case (1/16) as the patient was lost to follow-up immediately post-procedure. The one-year patency rate was 100%. A significant reduction was observed in the median number of IR visits (8 [1-51] to 1 [0-9]; P = .003) and drain insertion/exchange procedures (5 [1-45] to 0 [0-6]; P = .003) pre- and post-EB-RFA with a median follow-up of 18 (0-26) months.
Percutaneous EB-RFA can safely and effectively treat refractory benign biliary strictures. However, larger prospective studies with extended follow-ups are needed to gather more robust data.
This study contributes to the limited evidence on the role of EB-RFA in addressing refractory benign biliary strictures, enhancing the understanding of its clinical utility.
评估经皮肝内胆管射频消融术(EB-RFA)治疗难治性良性胆管狭窄的安全性和有效性。
对15例(男/女 = 8/7;中位年龄:57岁[33 - 84岁])对传统方法(经皮肝穿刺胆管成形术和胆管引流)治疗无效的良性胆管狭窄患者进行经皮EB-RFA治疗。所有患者在术前均接受了≥1次不成功的胆管成形术,并对其经皮肝穿刺胆管引流管进行了升级。技术成功定义为管腔增宽且血流增加,临床成功定义为在拔除引流管/支架后的随访中无明显临床复发狭窄。
共进行了16次EB-RFA手术。技术成功率为100%(16/16)。手术相关并发症发生1例(1/16)(引流管渗漏继发蜂窝织炎)。临床成功率为87%(13/15),中位随访时间为17个月(2 - 24个月)。1例(1/16)患者术后失访,未拔除引流管/支架。1年通畅率为100%。在中位随访18个月(0 - 26个月)时,观察到EB-RFA术前和术后介入放射学检查次数中位数(从8次[1 - 51次]降至1次[0 - 9次];P = 0.003)和引流管置入/更换次数中位数(从5次[1 - 45次]降至0次[0 - 6次];P = 0.003)显著减少。
经皮EB-RFA可安全有效地治疗难治性良性胆管狭窄。然而,需要进行更大规模的前瞻性研究并延长随访时间以收集更有力的数据。
本研究为EB-RFA在治疗难治性良性胆管狭窄中的作用提供了有限的证据,增进了对其临床应用的理解。